This site is intended for U.S. healthcare professionals.

IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.


Differentiation Syndrome With IDHIFA® Video Thumbnail

Dr Harry Erba and Marilyn Pritchard, RN, have been paid by Bristol Myers Squibb to participate in this video.


  1. Data on file, Celgene Corporation. Summit, New Jersey.